Abstract
Background: Autoimmune disease is a refractory disease. Accumulating Evidence has revealed that the manipulation of mesenchymal stem cells may have the potential to control or even treat autoimmune diseases. Human gingiva-derived mesenchymal stem cells (GMSCs) are emerging as a new line of mesenchymal stem cells that have displayed some potential advantages in controlling and treating autoimmune diseases.
Objective: In this review, we briefly update the current understanding on the biology of GMSCs and their effects on preventing and treating autoimmune diseases.
Conclusion: The availability of gingival mesenchymal stem cells (GMSCs), together with their potent capacity of multi-directional differentiation and inflammatory modulation, making GMSCs an ideal subtype of MSCs in treating autoimmune disease. Our and other studies have launched the earliest appraisal on GMSCs and carried out a lot of biological researches. The clinical trial of GMSCs on patients with autoimmune diseases will further approve their therapeutic effects, as well as its cellular and molecular mechanisms.
Keywords: Autoimmune diseases, mesenchymal stem cells, human gingiva-derived mesenchymal stem cells, bone marrowderived mesenchymal stem cells, cell therapy.
Current Stem Cell Research & Therapy
Title:Updates on GMSCs Treatment for Autoimmune Diseases
Volume: 13 Issue: 5
Author(s): Feng Huang, Zhong Ming Liu and Song Guo Zheng*
Affiliation:
- Department of Medicine, Milton S. Hershey Medical Center, Penn State University, Hershey, PA, 17033,United States
Keywords: Autoimmune diseases, mesenchymal stem cells, human gingiva-derived mesenchymal stem cells, bone marrowderived mesenchymal stem cells, cell therapy.
Abstract: Background: Autoimmune disease is a refractory disease. Accumulating Evidence has revealed that the manipulation of mesenchymal stem cells may have the potential to control or even treat autoimmune diseases. Human gingiva-derived mesenchymal stem cells (GMSCs) are emerging as a new line of mesenchymal stem cells that have displayed some potential advantages in controlling and treating autoimmune diseases.
Objective: In this review, we briefly update the current understanding on the biology of GMSCs and their effects on preventing and treating autoimmune diseases.
Conclusion: The availability of gingival mesenchymal stem cells (GMSCs), together with their potent capacity of multi-directional differentiation and inflammatory modulation, making GMSCs an ideal subtype of MSCs in treating autoimmune disease. Our and other studies have launched the earliest appraisal on GMSCs and carried out a lot of biological researches. The clinical trial of GMSCs on patients with autoimmune diseases will further approve their therapeutic effects, as well as its cellular and molecular mechanisms.
Export Options
About this article
Cite this article as:
Huang Feng , Liu Ming Zhong and Zheng Guo Song *, Updates on GMSCs Treatment for Autoimmune Diseases, Current Stem Cell Research & Therapy 2018; 13 (5) . https://dx.doi.org/10.2174/1574888X13666180220141114
DOI https://dx.doi.org/10.2174/1574888X13666180220141114 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Parvovirus B19: An Infectious Agent with the Potential to Induce and Trigger Rheumatic Disease
Current Rheumatology Reviews Pathophysiology of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Identification of Expressed miRNAs in Human Rheumatoid Arthritis Using Computational Approach – Discovery of a New miR-7167 from Human
MicroRNA Synthesis and Immunosuppressive Activity of New Mycophenolic Acid Derivatives
Medicinal Chemistry Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Current Topics in Medicinal Chemistry Impact of Hydroxyl Radical Modified-Human Serum Albumin Autoantigens in Systemic Lupus Erythematosus
Current Protein & Peptide Science Insights into the Pathogenesis of Type 1 Diabetes A Hint for Novel Immunospecific Therapies
Current Molecular Medicine Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Targeted Therapies – Many Ways to (the Peace of) Rome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Development and Chemistry of Histamine H4 Receptor Ligands as Potential Modulators of Inflammatory and Allergic Responses
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Influence of Genetic Polymorphisms on Mycophenolic Acid Pharmacokinetics and Patient Outcomes in Renal Transplantation
Current Drug Metabolism Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design A Comparison of Biological Activity of B Lymphocyte Stimulator (BLyS) Antagonist Peptibodies and the Elucidation of Possible BLyS Binding Sites
Protein & Peptide Letters Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy
Letters in Drug Design & Discovery Ganglioside Mimicry as a Cause of Guillain-Barre Syndrome
CNS & Neurological Disorders - Drug Targets Systemic Lupus Erythematosus and Other Autoimmune Diseases from Endogenous and Exogenous Agents: Unifying Theme of Oxidative Stress
Mini-Reviews in Medicinal Chemistry Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets